Stock News & Analysis

Its third-quarter revenue and profitability fell short of analyst estimates.

GXO missed revenue estimates in the second quarter, but the components for an acceleration are coming together.

Nova's stake surged 526% following a year of minimal stock gains, signaling confidence in the motorcycle maker's turnaround prospects.

Fedena reduced his direct equity stake by 18% following a 213% one-year stock surge, while maintaining a 0.11% ownership interest in the refiner.

Chemours reported a lackluster second quarter, given the enthusiasm for its AI business heading in.

Eryk Spytek's sale was non-discretionary, triggered by tax withholding on vested performance awards. His total equity stake remains substantial at $2.44 million across direct and trust holdings.

The company's exposure to OpenAI remains the main talking point among equity and bond investors.

Lei Zhang Schlitz sold 61% of his direct holdings as JCI stock surged 44% over the past year. He retains 15,017 shares worth roughly $2.31 million.

AWS is overshadowing Amazon's e-commerce operations.

Insider purchased shares at $9.81 each, a 2% discount to market close, boosting his total beneficial position to 8.2 million shares.

The 4% withdrawal rule was established more than 30 years ago. Thanks to new research, its founder says that rate is likely much too low.

Duolingo's second-quarter earnings will reveal more than just another set of financial results.

SCHE offers lower fees and higher yields, while NZAC provides ESG-screened global exposure with 625 holdings. One prioritizes emerging market growth; the other emphasizes climate-aligned investing.

Even though PayPal never directly addressed Stripe's recent buyout offer in its earnings report, the message was clear: It's too low.

The share price puts this company in stock-split territory, but it may need to go even higher before management considers one.

Chinese memory maker CXMT went public and gained nearly 500% on its opening day.

Strategy plans to sell more Bitcoin to cover its buybacks and preferred stock dividends.

Clorox is a great value for income investors.

XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside.

Don't let their recent poor performances chase you away.